Prabtha is doing excalty what a great CEO would do: she is setting the table for a buyout or a going it alone approach. The two alternatives dictate the same strategy. The worst situation would be if CEMP sat on its hands waiting for a low ball offer from Merck or other big pharma based solely on clinical results. Acquisition alternative can be facilitated by all the strategizing and implementation that has been undertaken pre acquisition. If acquisition does not occur, CEMP proceeds eyes wide open. Win win Prabtha and her team are par excellence. She can't and won't tell us all that is going through her and the team's collective minds.
Pardon me, but if that is the way you analyze the situation (and you have proffered no analysis, just conclusions), by all means sell and leave this board. Prabtha is perfectly teeing CEMP for a sale at a high price.
Thanks for the reminder. I agree with your comment. As for Schroe's earlier comment, he is correct, but I have the conviction that the payoff will come much sooner. All of the preparation for launch is likely window dressing/insurance and is not a definitive indicator of a desire to go it alone. Among other things, Prabtha is 67 and I imagine would just as soon cash out upon regulatory approval.